Revenue GrowthSustained TTM revenue growth of +27.7% signals expanding product adoption and market traction in the medical instruments market. A durable top-line expansion provides capacity to scale operations, invest in R&D and distribution, and eventually absorb fixed costs as the business matures.
Improved Cash GenerationA material improvement to operating cash flow and positive free cash flow improves near-term liquidity and funds operations without immediate external financing. If sustained, this enhances survivability and strategic optionality to fund growth, capex, or deleveraging over the coming months.
Moderate Current LeverageDebt-to-equity near 0.69 indicates leverage that supports growth financing but is not currently extreme. This provides capacity to invest while retaining manageable obligations, assuming cash generation stays positive, offering a structural cushion versus highly levered peers.